New hope for tough pancreatic cancer? early trial tests immune boosts

NCT ID NCT04787991

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-phase trial tested different combinations of immunotherapy drugs with standard chemotherapy for people with metastatic pancreatic cancer that had not been treated before. The main goal was to check safety and see if the combinations could shrink tumors or control the disease. 45 participants were enrolled in this exploratory study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M.D. Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Stanford University

    Stanford, California, 94305, United States

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • University of California, San Francisco

    San Francisco, California, 94143, United States

  • University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania, 19104, United States